Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules

Nikita Abramenko,Fréderic Vellieux,Kateřina Veselá,Zdeněk Kejík,Jan Hajduch,Michal Masařík,Petr Babula,David Hoskovec,Karel Pacák,Pavel Martásek,Karel Smetana,Milan Jakubek

DOI: https://doi.org/10.1038/s41598-024-51804-2

IF: 4.6

2024-02-07

Scientific Reports

Abstract:Immune checkpoints regulate the immune system response. Recent studies suggest that flavonoids, known as phytoestrogens, may inhibit the PD-1/PD-L1 axis. We explored the potential of estrogens and 17 Selective Estrogen Receptor Modulators (SERMs) as inhibiting ligands for immune checkpoint proteins (CTLA-4, PD-L1, PD-1, and CD80). Our docking studies revealed strong binding energy values for quinestrol, quercetin, and bazedoxifene, indicating their potential to inhibit PD-1 and CTLA-4. Quercetin and bazedoxifene, known to modulate EGFR and IL-6R alongside estrogen receptors, can influence the immune checkpoint functionality. We discuss the impact of SERMs on PD-1 and CTLA-4, suggesting that these SERMs could have therapeutic effects through immune checkpoint inhibition. This study highlights the potential of SERMs as inhibitory ligands for immune checkpoint proteins, emphasizing the importance of considering PD-1 and CTLA-4 inhibition when evaluating SERMs as therapeutic agents. Our findings open new avenues for cancer immunotherapy by exploring the interaction between various SERMs and immune checkpoint pathways.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper attempts to address the potential of selective estrogen receptor modulators (SERMs) as inhibitors of immune checkpoint proteins (such as CTLA-4, PD-L1, PD-1, and CD80). Specifically, the study evaluates the potential inhibitory effects of 17 selective estrogen receptor modulators (SERMs) and several estrogens on these immune checkpoint proteins through molecular docking methods. The main objective of the study is to discover whether these compounds can inhibit the function of immune checkpoint proteins by binding to them, thereby providing new candidate drugs for cancer immunotherapy.

The research background includes:
1. Immune checkpoint proteins play a crucial role in regulating immune system responses, and tumor cells often evade immune surveillance by upregulating co-inhibitory molecules.
2. Recent studies suggest that flavonoids (a type of phytoestrogen) may have inhibitory effects on the PD-1/PD-L1 axis.
3. Estrogens and their receptor modulators play important roles in various physiological processes, including antiviral activity, cardiovascular system support, and respiratory system protection.

The research methods mainly include:
1. Using molecular docking techniques to evaluate the binding ability of 17 SERMs with immune checkpoint proteins (CTLA-4, PD-L1, PD-1, and CD80).
2. Calculating binding energy values to screen for compounds with strong binding affinity.
3. Analyzing the binding modes of these compounds with immune checkpoint proteins to explore their potential inhibitory mechanisms.

The research results indicate that certain SERMs, such as quinestrol, quercetin, and bazedoxifene, exhibit strong binding abilities and may have inhibitory effects on PD-1 and CTLA-4. These findings provide a theoretical basis for the development of new immune checkpoint inhibitors and are expected to open new research directions in the field of cancer immunotherapy.